Auto saved by Logseq

master
Borja FMS 4 months ago
parent 53f60ecc58
commit da1264219a

@ -1,25 +1,24 @@
- TODO CONTAR a [[Nerea]] con cosas importantes para [[STOP2030/Redes Sociales]] y otras cosas
id:: 66d58211-5274-456c-b2d3-3f6361df7028
SCHEDULED: <2024-09-06 Fri>
- ASTMH y otros eventos del futuro (que aunque no vayamos pueden ser relevantes para contenido, redes, etc.)
- TODO QUE METAN en la [[Web]] de [[STOP2030]] que [[OMS]] ha designado a [[KEMRI]] como un centro colaborador en la vigilancia de NTDs [https://apps.who.int/whocc/Detail.aspx?XOAHM3sF/C/9r825fA94LA==](https://apps.who.int/whocc/Detail.aspx?XOAHM3sF/C/9r825fA94LA==)
collapsed:: true
SCHEDULED: <2024-09-06 Fri>
- Escrito un textito:
- #+BEGIN_VERSE
**ESACIPAC (KEMRI) designated as a WHO Collaborating Centre on monitoring and evaluation of NTDs**
The Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), a part of KEMRI, has been designated as a WHO Collaborating Centre on monitoring and evaluation of neglected tropical diseases (NTDs) for the next four years. As part of their commitment, they will carry out activities to support disease mapping and impact assessment surveys for the control and elimination of NTDs.
This newly designated WHO Collaborating Centre will be led by Doris Njomo, PhD, centre director of ESACIPAC, and Collins Okoyo, PhD, a statistician from KEMRI involved in the data collection, modelling and analysis within the STOP2030 consortium.
The STOP2030 consortium congratulates ESACIPAC, and KEMRI, for this important achievement, and celebrates working together in developing our fixed-dose coformulation and making it available where it is most needed.
#+END_VERSE
- LO de KEMRI y OMS
- La nueva guía de Strongy
- En breve el DTAG publicará the TPP on diagnostics for St st. With that, these recommendations should have the right tools to complement treatment.
- El paper de farmacocinética. La clave está en la última frase del abstract: "The results allow the advancement to the next phase of the clinical program to demonstrate efficacy and safety in patients affected by soil-transmitted helminths.". https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329971/
-
- # #Tareas
- TODO CONTAR a [[Nerea]] con cosas importantes para [[STOP2030/Redes Sociales]] y otras cosas
id:: 66d58211-5274-456c-b2d3-3f6361df7028
SCHEDULED: <2024-09-06 Fri>
- ASTMH y otros eventos del futuro (que aunque no vayamos pueden ser relevantes para contenido, redes, etc.)
- TODO QUE METAN en la [[Web]] de [[STOP2030]] que [[OMS]] ha designado a [[KEMRI]] como un centro colaborador en la vigilancia de NTDs [https://apps.who.int/whocc/Detail.aspx?XOAHM3sF/C/9r825fA94LA==](https://apps.who.int/whocc/Detail.aspx?XOAHM3sF/C/9r825fA94LA==)
SCHEDULED: <2024-09-06 Fri>
- Escrito un textito:
- #+BEGIN_VERSE
**ESACIPAC (KEMRI) designated as a WHO Collaborating Centre on monitoring and evaluation of NTDs**
The Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), a part of KEMRI, has been designated as a WHO Collaborating Centre on monitoring and evaluation of neglected tropical diseases (NTDs) for the next four years. As part of their commitment, they will carry out activities to support disease mapping and impact assessment surveys for the control and elimination of NTDs.
This newly designated WHO Collaborating Centre will be led by Doris Njomo, PhD, centre director of ESACIPAC, and Collins Okoyo, PhD, a statistician from KEMRI involved in the data collection, modelling and analysis within the STOP2030 consortium.
The STOP2030 consortium congratulates ESACIPAC, and KEMRI, for this important achievement, and celebrates working together in developing our fixed-dose coformulation and making it available where it is most needed.
#+END_VERSE
- LO de KEMRI y OMS
- La nueva guía de Strongy
- En breve el DTAG publicará the TPP on diagnostics for St st. With that, these recommendations should have the right tools to complement treatment.
- El paper de farmacocinética. La clave está en la última frase del abstract: "The results allow the advancement to the next phase of the clinical program to demonstrate efficacy and safety in patients affected by soil-transmitted helminths.". https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329971/
-
Loading…
Cancel
Save